Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07706166 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Letermovir for R+ Study

Study acronym: MISP CMV
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date pushed from Sep 2026 to Oct 2026
  2. Secondary endpoints: details revised at 1 of 1 entry
    • Collaborators: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 5 words
  3. Primary and study completion dates: Aug 2029 to Sep 2029
    • Start date: Aug 2026 to Sep 2026
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.
Trial Details
NCT Number NCT07706166
Lead Sponsor University of Wisconsin, Madison
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Kidney Transplant, Liver Transplant
Enrollment 146 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov